Advertisement
Screener

Alector, Inc. (ALEC) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

Alector, Inc. Operating Expenses

Alector, Inc. (ALEC) reported Operating Expenses of $27.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-06

  • Alector, Inc. operating expenses for the quarter ending 2026-06-30 was $27.71M, a 34.04% decline year-over-year.
  • Alector, Inc. operating expenses for the quarter ending 2026-03-31 was $25.96M, a 46.32% decline year-over-year.
  • Alector, Inc. operating expenses for the quarter ending 2025-12-31 was $45.80M, a 25.51% decline year-over-year.
  • Alector, Inc. operating expenses for the quarter ending 2025-09-30 was $40.87M, a 35.92% decline year-over-year.
  • Alector, Inc. operating expenses for fiscal 2025 was $177.05M, a 27.90% decline from fiscal 2024.
  • Alector, Inc. operating expenses for fiscal 2024 was $245.56M, a 1.31% decline from fiscal 2023.
  • Alector, Inc. operating expenses for fiscal 2023 was $248.80M, a 8.34% decline from fiscal 2022.
  • Alector, Inc. operating expenses for fiscal 2022 was $271.45M, a 11.05% increase from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 6 monthOperating Expenses 9 monthOperating Expenses 12 month
2026-06-30$27.71M
10-Q · filed 2026-08-06
$53.68M
10-Q · filed 2026-08-06
$99.48M
derived: sum of 3 quarters · filed 2026-08-06
$140.35M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$25.96M
10-Q · filed 2026-05-07
$71.77M
derived: sum of 2 quarters · filed 2026-05-07
$112.64M
derived: sum of 3 quarters · filed 2026-05-07
$154.65M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$45.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$86.67M
derived: sum of 2 quarters · filed 2026-02-25
$128.68M
derived: sum of 3 quarters · filed 2026-08-06
$177.05M
10-K · filed 2026-02-25
2025-09-30$40.87M
10-Q · filed 2025-11-06
$82.88M
derived: sum of 2 quarters · filed 2026-08-06
$131.25M
10-Q · filed 2025-11-06
$192.74M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$42.01M
10-Q · filed 2026-08-06
$90.38M
10-Q · filed 2026-08-06
$151.87M
derived: sum of 3 quarters · filed 2026-08-06
$215.65M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$48.37M
10-Q · filed 2026-05-07
$109.86M
derived: sum of 2 quarters · filed 2026-05-07
$173.63M
derived: sum of 3 quarters · filed 2026-05-07
$234.32M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$61.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$125.27M
derived: sum of 2 quarters · filed 2026-02-25
$185.95M
derived: sum of 3 quarters · filed 2026-02-25
$245.56M
10-K · filed 2026-02-25
2024-09-30$63.78M
10-Q · filed 2025-11-06
$124.47M
derived: sum of 2 quarters · filed 2025-11-06
$184.07M
10-Q · filed 2025-11-06
$246.71M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$60.69M
10-Q · filed 2025-08-07
$120.29M
10-Q · filed 2025-08-07
$182.93M
derived: sum of 3 quarters · filed 2025-08-07
$242.63M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$59.60M
10-Q · filed 2025-05-08
$122.24M
derived: sum of 2 quarters · filed 2025-05-08
$181.94M
derived: sum of 3 quarters · filed 2025-05-08
$241.74M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$62.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$122.33M
derived: sum of 2 quarters · filed 2025-02-26
$182.14M
derived: sum of 3 quarters · filed 2025-02-26
$248.80M
10-K · filed 2025-02-26
2023-09-30$59.69M
10-Q · filed 2024-11-06
$119.50M
derived: sum of 2 quarters · filed 2024-11-06
$186.16M
10-Q · filed 2024-11-06
$256.04M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$59.80M
10-Q · filed 2024-08-07
$126.47M
10-Q · filed 2024-08-07
$196.34M
derived: sum of 3 quarters · filed 2025-02-26
$258.94M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$66.66M
10-Q · filed 2024-05-08
$136.54M
derived: sum of 2 quarters · filed 2025-02-26
$199.14M
derived: sum of 3 quarters · filed 2025-02-26
$269.52M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$69.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$132.48M
derived: sum of 2 quarters · filed 2025-02-26
$202.85M
derived: sum of 3 quarters · filed 2025-02-26
$271.45M
10-K · filed 2025-02-26
2022-09-30$62.60M
10-Q · filed 2023-11-07
$132.98M
derived: sum of 2 quarters · filed 2023-11-07
$201.57M
10-Q · filed 2023-11-07
$271.30M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30$70.38M
10-Q · filed 2023-08-03
$138.97M
10-Q · filed 2023-08-03
$208.70M
derived: sum of 3 quarters · filed 2024-02-27
$264.78M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31$68.60M
10-Q · filed 2023-05-04
$138.32M
derived: sum of 2 quarters · filed 2024-02-27
$194.40M
derived: sum of 3 quarters · filed 2024-02-27
$256.30M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31$69.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
$125.81M
derived: sum of 2 quarters · filed 2024-02-27
$187.70M
derived: sum of 3 quarters · filed 2024-02-27
$244.44M
10-K · filed 2024-02-27
2021-09-30$56.08M
10-Q · filed 2022-11-08
$117.98M
derived: sum of 2 quarters · filed 2022-11-08
$174.72M
10-Q · filed 2022-11-08
$232.33M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$61.89M
10-Q · filed 2022-08-04
$118.64M
10-Q · filed 2022-08-04
$176.25M
derived: sum of 3 quarters · filed 2023-02-28
$235.90M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$56.74M
10-Q · filed 2022-05-05
$114.36M
derived: sum of 2 quarters · filed 2023-02-28
$174.01M
derived: sum of 3 quarters · filed 2023-02-28
$223.77M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$57.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$117.26M
derived: sum of 2 quarters · filed 2023-02-28
$167.02M
derived: sum of 3 quarters · filed 2023-02-28
$216.27M
10-K · filed 2023-02-28
2020-09-30$59.65M
10-Q · filed 2021-11-04
$109.41M
derived: sum of 2 quarters · filed 2021-11-04
$158.66M
10-Q · filed 2021-11-04
$197.00M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$49.76M
10-Q · filed 2021-08-03
$99.01M
10-Q · filed 2021-08-03
$137.35M
derived: sum of 3 quarters · filed 2022-02-24
$174.20M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$49.25M
10-Q · filed 2021-05-05
$87.59M
derived: sum of 2 quarters · filed 2022-02-24
$124.44M
derived: sum of 3 quarters · filed 2022-02-24
$158.51M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$38.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$75.19M
derived: sum of 2 quarters · filed 2022-02-24
$109.26M
derived: sum of 3 quarters · filed 2022-02-24
$135.62M
10-K · filed 2022-02-24
2019-09-30$36.84M
10-Q · filed 2020-11-10
$70.91M
derived: sum of 2 quarters · filed 2020-11-10
$97.28M
10-Q · filed 2020-11-10
$125.44M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$34.07M
10-Q · filed 2020-08-11
$60.44M
10-Q · filed 2020-08-11
$88.60M
derived: sum of 3 quarters · filed 2021-02-25
$111.92M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$26.37M
10-Q · filed 2020-05-13
$54.53M
derived: sum of 2 quarters · filed 2021-02-25
$77.85M
derived: sum of 3 quarters · filed 2021-02-25
$97.19M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$28.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$51.48M
derived: sum of 2 quarters · filed 2021-02-25
$70.82M
derived: sum of 3 quarters · filed 2021-02-25
$84.97M
10-K · filed 2021-02-25
2018-09-30$23.32M
10-Q · filed 2019-11-12
$42.66M
derived: sum of 2 quarters · filed 2019-11-12
$56.80M
10-Q · filed 2019-11-12
2018-06-30$19.34M
10-Q · filed 2019-08-12
$33.48M
10-Q · filed 2019-08-12
2018-03-31$14.14M
10-Q · filed 2019-05-13
2017-12-31$36.41M
10-K · filed 2020-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99